Trial Profile

A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in Combination With Daratumumab Compared With Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 20 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Melphalan flufenamide (Primary) ; Daratumumab; Dexamethasone; Dexamethasone
Indications Multiple myeloma
Focus Registrational; Therapeutic Use
Acronyms LIGHTHOUSE
Sponsors Oncopeptides

11 Nov 2022 According to a Oncopeptides media release, based on the data of HORIZON, OCEAN and LIGHTHOUSE studies, the company has received the grant for the marketing authorization for Pepaxti in combination with dexamethasone, by the Medicines & Healthcare products Regulatory Agency, MHRA, in UK.
26 Oct 2022 Results presented in an Oncopeptides media release.
07 Mar 2022 This trial has been completed in Norway (Date of the global end of the trial : 07-Feb-2022), according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com